| Dr Katelyn P Steele, MD | |
|
670 Ponahawai St Ste 206, Hilo, HI 96720-7830 | |
| (808) 238-0947 | |
| (808) 437-2059 |
| Full Name | Dr Katelyn P Steele |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 6 Years |
| Location | 670 Ponahawai St Ste 206, Hilo, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609372861 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD-20736 (Hawaii) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hilo Urgent Care Center Llc | 7214825231 | 7 |
News Archive
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
Patients around the world will benefit from better training and testing of health professionals as USF Health opens its $38 million Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa.
Alcon, the world's leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 6 days ago
| Entity Name | Hilo Urgent Care Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487750089 PECOS PAC ID: 7214825231 Enrollment ID: O20040310000188 |
News Archive
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
Patients around the world will benefit from better training and testing of health professionals as USF Health opens its $38 million Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa.
Alcon, the world's leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 6 days ago
| Entity Name | Maika'i Health Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891301016 PECOS PAC ID: 5597153049 Enrollment ID: O20211102002544 |
News Archive
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
Patients around the world will benefit from better training and testing of health professionals as USF Health opens its $38 million Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa.
Alcon, the world's leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Katelyn P Steele, MD 670 Ponahawai St Ste 206, Hilo, HI 96720-7830 Ph: (808) 238-0947 | Dr Katelyn P Steele, MD 670 Ponahawai St Ste 206, Hilo, HI 96720-7830 Ph: (808) 238-0947 |
News Archive
Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations.
Patients around the world will benefit from better training and testing of health professionals as USF Health opens its $38 million Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa.
Alcon, the world's leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 6 days ago
Jesse C. Maag, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1292 Waianuenue Ave, Hilo, HI 96720 Phone: 808-934-4000 | |
Melanie R Arakaki, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 670 Ponahawai St, Ste 216 Hilo Family Medicine, Hilo, HI 96720 Phone: 808-934-8989 Fax: 808-934-8990 | |
Hamed Ahmadinia, M.D Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 45 Mohouli St Ste 201, Hilo, HI 96720 Phone: 808-932-3186 | |
Mr. Gaku Yamaguchi, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1438 Kilauea Ave, Hilo, HI 96720 Phone: 808-969-9220 | |
Timothy S Duerler, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Puuhonu Pl, Ste 205, Hilo, HI 96720 Phone: 808-933-2399 | |
Adam H Adler, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1292 Waianuenue Ave, Hilo, HI 96720 Phone: 808-934-4000 | |
Dr. Andrew Chang, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1190 Waianuenue Ave, Hilo, HI 96720 Phone: 808-932-4215 |